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Abstract
Genetic subgrouping of gliomas has been emphasized recently, particularly after the find-
ing of isocitrate dehydrogenase 1 (IDH1) mutations. In a previous study, we investigated
whole-chromosome copy number aberrations (CNAs) of gliomas and have described
genetic subgrouping based on CNAs and IDH1mutations. Subsequently, we classified gli-
omas using simple polymerase chain reaction (PCR)-based methods to improve the avail-
ability of genetic subgrouping. We selected IDH1/2 and TP53 as markers and analyzed
237 adult supratentorial gliomas using Sanger sequencing. Using these markers, we clas-
sified gliomas into three subgroups that were strongly associated with patient prognoses.
These included IDHmutant gliomas without TP53mutations, IDHmutant gliomas with
TP53mutations, and IDH wild-type gliomas. IDHmutant gliomas without TP53mutations,
which mostly corresponded to gliomas carrying 1p19q co-deletions, showed lower recur-
rence rates than the other 2 groups. In the other high-recurrence groups, the median pro-
gression-free survival (PFS) and overall survival (OS) of patients with IDHmutant gliomas
with TP53mutations were significantly longer than those of patients with IDH wild-type glio-
mas. Notably, most IDHmutant gliomas with TP53mutations had at least one of the CNAs
+7q, +8q, −9p, and −11p. Moreover, IDHmutant gliomas with at least one of these CNAs
had a significantly worse prognosis than did other IDHmutant gliomas. PCR-based muta-
tion analyses of IDH and TP53 were sufficient for simple genetic diagnosis of glioma that
were strongly associated with prognosis of patients and enabled us to detect negative
CNAs in IDHmutant gliomas.
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Introduction
Gliomas are currently classified according to their histological appearance, and the associated
malignancy is defined by the World Health Organization (WHO) grading system. In cases of
high grade gliomas, patients tend to show high recurrence rates and a worse prognosis. However,
in some cases, the clinical course does not reflect the histological classification, warranting the
use of genetic diagnoses and subgroups. We previously reported that adult supratentorial gliomas
could be classified into genetic subgroups on the basis of their copy number aberrations (CNAs)
using comparative genomic hybridization (CGH) and suggested that gliomas with +7q and 1p/
19q co-deletions may have a better prognosis than those with −9p, −10q, and +7 CNAs [1].
The clinical significance of isocitrate dehydrogenase 1 (IDH1) point mutation in gliomas
was first reported in 2008, the overall survival (OS) of glioblastoma patients with IDH1-
mutated glioblastoma was demonstrated to be significantly longer than that of patients with
wild-type IDH1 glioblastoma [2]. Various subsequent studies confirmed the prognostic impor-
tance of IDH1mutations [3–6]. Therefore, we combined a CGH analysis with the IDH1muta-
tion status to propose the genetic subgrouping of gliomas [5]. The data demonstrated that
IDH1mutant gliomas with −1p/19q and +7q CNAs are associated with a better prognosis than
that associated with IDH1 wild-type gliomas.
Although these genetic subgroups were clinically informative, copy number-independent
and simplified methods are desirable for genetic classification in clinical use. Therefore, in the
present study we aimed to identify simpler and more widely available methods by which glio-
mas could be diagnosed at many clinical institutions. We focused on Sanger sequencing to
address this problem and selected IDH1/2 and TP53 as markers for polymerase chain reaction
(PCR) analyses. IDH2mutations were first detected in gliomas by Yan et al. [3]; similar to
IDH1mutations, IDH2mutation were associated with a better prognosis, although these muta-
tions occurred at considerable lower frequency. Moreover, TP53mutations are often detected
in astrocytic tumors [7] and it has been shown that these are mutually exclusive with 1p/19q
co-deleted gliomas [8]. Therefore, we hypothesized that most IDHmutant gliomas without
TP53mutations carry 1p/19q co-deletions.
Given the increase in CNAs with tumor regrowth or progression to high grade gliomas,
according to our CGH analyses, the identification of common and specific CNAs for each
genetic subgroup should facilitate an oncological understanding of gliomas. Although we pre-
viously reported that 1p/19q co-deletions and +7q are frequently detected in IDHmutant glio-
mas [5] according to our CGH data, only 68% of IDHmutant gliomas harbored 1p/19q co-
deletions and/or +7q. Therefore, in this study, we also aimed to identify common CNAs in
IDHmutant gliomas, particularly those harboring TP53mutation.
In the present study, we analyzed IDH1/2 and TP53mutations in adult supratentorial glio-
mas via direct sequencing and characterized these malignancies using PCR-based genetic sub-
grouping, achieving greater prognostic accuracy than that achieved with pathological
classifications. In addition, we confirmed that most IDHmutant gliomas with TP53mutations
contained at least one of the CNAs +7q, +8q, −9p, and −11p. Because IDHmutant gliomas
with TP53mutations showed high recurrence rates, we suggest that these CNAs are negative
prognostic factors for patients with IDHmutant gliomas.
Materials and Methods
Patients, samples, and DNA preparation
We analyzed 237 adult supratentorial glioma samples that had been surgically resected at Keio
University from 1994 until 2004 and at Fujita Health University from 2001 until 2015. The
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histological diagnoses included (anaplastic) astrocytomas, (anaplastic) oligodendrogliomas,
(anaplastic) oligoastrocytomas, and glioblastomas. Some patients underwent2 surgeries dur-
ing their clinical course, thereby contributing to multiple glioma samples. The samples were
evaluated by neuropathologists and were classified according to the WHO criteria. Tumor
samples were available as frozen tissues and/or as formalin-fixed paraffin-embedded (FFPE)
samples. DNA was extracted from freshly frozen tissue using DNeasy blood and tissue kits
(QIAGEN) and from FFPE samples with DNA FFPE tissue kits (QIAGEN) or REPLI-g kits
(QIAGEN). DNA quality was assessed via absorptiometric analyses. This study was approved
by the Ethics Committee of the Fujita Health University (Approval number: 11–106). Written
informed consent was obtained from each patient.
CGH
The CGH analysis was conducted as described by Hirose et al. [1]. Tumor tissues were
removed from FFPE samples according to pathological appearance or MIB-1 density and
tumor DNA was amplified via degenerate oligonucleotide-primed PCR (DOP-PCR). DNA
from peripheral blood lymphocytes was obtained from healthy donors and was used as a con-
trol. DNA from these samples was labeled with biotin–deoxyuridine triphosphate (Roche)
after amplification. Subsequently, labeled DNA from tumors and normal tissues was hybrid-
ized to normal metaphase spreads. After unhybridized probes were washed away, the spreads
were counterstained with 4,6-diamino-2-phenylindole and the fluorescence intensity ratios for
each chromosome were assessed using CytoVision software (Applied Imaging).
As described previously, total chromosomal gains and partial gains, such as +7 and +7q,
were interpreted as different CNAs [5]; +7 was interpreted as a typical copy number change for
IDH wild-type gliomas and +7q was often detected in IDHmutant gliomas. Because gliomas
with and without IDHmutations are thought to be evolved through different lineages [5], we
assumed that the total and partial chromosomal gains would reflect different processes. How-
ever, we considered total loss and partial losses (such as −10 and −10q) to be identical CNAs,
although they were frequently detected in IDH wild-type gliomas that did not show differences
in prognosis or histology. Accordingly, we categorized −10 and −10q as −10q.
Mutation analysis
Sanger sequencing was used to detect IDH1/2 and TP53mutations in the samples. We analyzed
the sequence of codon 132 for IDH1 and codon 172 for IDH2. In previous studies, most TP53
missense mutation hotspots were found in exons 5–8 [9–11], and missense mutations in the
DNA-binding domains affected the prognosis of patients with breast carcinoma [12]; therefore,
we investigated exons 5–8 in TP53mutation analyses. The primers used in our study were
selected according to previous studies [10, 13–15], and sequence analyses were conducted
using ABI 3100 apparatus (Applied Biosystems).
Statistical analysis
The primary endpoint in this study was progression-free survival (PFS), which is defined as the
period from the date of first surgery until the confirmation of tumor regrowth via magnetic reso-
nance imaging (MRI) or symptomatic deterioration. Prognoses were calculated according to PFS
and OS, another important factor with respect to a patient’s prognosis. OS was defined as the
period from the date of first surgery until the date of death. Kaplan–Meier curves were generated
in cases involving first surgery. Cox log-rank tests were used for group comparison. A multivari-
ate logistic regression analysis was conducted to examine correlation between recurrence within
3 years and clinical factors, histology, or specific CNAs. We selected 3 years as the cut-off for
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recurrence since the median PFS of IDHmutant gliomas ranged from 42 to 51 months according
to our patient data and a previous study [16] and excluded cases if follow-up months were less
than 36 months. We defined subtotal resection (STR) as a tumor resection volume of>90%.
Results
Comparison of the PCR-based genetic classification and histological
classification
The histological diagnosis of the 237 adult supratentorial gliomas evaluated in this study
included astrocytomas, oligodendrogliomas, oligoastrocytomas, and glioblastomas; IDH1/2
and TP53mutation statuses were determined via direct sequencing (S1 Fig). Among the 113
IDHmutant gliomas, 42 harbored TP53mutations and 42 did not. The remaining 29 samples
were from biopsies or were very old; thus those samples provided DNA of insufficient quantity
or quality for analyses. Because TP53mutations did not affect the prognosis of IDH wild-type
gliomas according to our study, we classified gliomas as IDHmutant gliomas without TP53
mutations, IDHmutant gliomas with TP53mutations, and IDH wild-type gliomas.
Fig 1 shows the prognoses of patients grouped according to histology or genetics.
Table present patients background information, including gender, age at diagnosis, recurrence
rates, median PFS, and median OS, for each histological and genetic subgroup, respectively. As
this was a retrospective study, the study cases had not undergone adjuvant therapy according to
strict regimen. Patients with IDH wild-type gliomas were significantly older than those with IDH
mutant gliomas (p< 0.05). Those harboring IDHmutant gliomas without TP53mutations had a
lower recurrence rate relative to the other two subgroups (p< 0.05). Although IDHmutant glio-
mas with TP53mutations and IDH wild-type gliomas were both associated with high recurrence
rates, the median PFS in the latter group was significantly shorter than that in the former group
(Table 1B and Fig 1C; hazard ratio = 0.229; 95% confidence interval [CI]: 0.142–0.368;
p< 0.0001). In these two genetic subgroups, the median OS of patients with IDH wild-type glio-
mas was also significantly shorter than that of patients with IDH and TP53mutant gliomas
(Table 1B and Fig 1D; hazard ratio = 0.270; 95% CI: 0.155–0.460; p< 0.0001). On the other hand,
the median OSs for grade III and IV gliomas were relatively similar (10 and 6 months, respec-
tively) although the difference between grade III and IV gliomas were statistically significant.
These results suggests that PCR-based genetic classification provides more precise clinical infor-
mation, which includes recurrence rates and PFS, than that provided by histological classification.
Results of CGH analysis in IDHmutant gliomas
In a previous study, we reported a high frequency of +7 and −10q CNAs among patients with
IDH1 wild-type gliomas [5]. In this study, we analyzed whole-chromosome gains and losses
and identified the CNAs frequently observed in IDHmutant gliomas with and without TP53
mutations (Fig 2). Notably, −1p was uniquely observed in IDHmutant gliomas without TP53
mutations and was always accompanied by −19q. Moreover, the CNAs −4q, +7, −14q, and
−19q were mainly detected in IDHmutant gliomas without TP53mutations. However, +7q
and −9p were more frequently found in IDHmutant gliomas with TP53mutations than in
other IDHmutant gliomas; +8q, −11p, and +12p were almost exclusively detected in IDH
mutant gliomas with TP53mutations.
Correlation between TP53mutation and CNAs in IDHmutant gliomas
We subsequently investigated the correlation between the TP53mutation and CNA statuses.
As expected, gliomas with TP53mutation and −1p/19q were mutually exclusive. Most IDH
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Fig 1. Kaplan–Meier curves of progression-free survival (PFS) according to subgroups. A comparison
of PFS and overall survival (OS) according to (A and B, respectively) pathological (n = 171) and (C and D,
respectively) genetic classification (n = 158). Kaplan–Meier curves comparing PFS (E) and OS (F)
associated with IDHmutant gliomas harboring CNAs +7q, +8q, −9p, and/or −11p with the PFS and OS of
other IDHmutant gliomas (n = 73). Only patients who underwent an initial surgical intervention were included
in these analyses. Abbreviations: mut; mutation, wt; wild-type.
doi:10.1371/journal.pone.0142750.g001
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Table 1. Background of patients who underwent initial surgical intervention.
A
WHO grade II (n = 63) WHO grade III (n = 48) WHO grade IV (n = 60)
Female 30 20 25
Age at
diagnosis
42.6 54.0 62.4
IDH mutation 53 30 2
Prognosis
Recurrent 28 33 50
Dropped 12 9 7
Following 23 6 3
Median PFS
(mo)
62 10 6
Median OS (mo) Undeﬁned 32 15
B
IDH mutant gliomas without TP53
mutation (n = 32)
IDH mutant gliomas with TP53
mutation (n = 29)
IDH wild-type gliomas
(n = 97)
Female 14 16 43
Age at
diagnosis
41.3 43.5 62.1
Histology
Oligo Grade II 19 9 3
Oligo Grade III 8 3 3
Astro Grade II 3 9 5
Astro Grade III 1 7 14
Astro Grade IV 1 0 55
Not deﬁned/
others
0 1 17
Additional
therapy
None 8 10 10
Radiotherapy only 4 2 9
Chemotherapy
only
14 5 12
Combined 5 12 62
Others or
unknown
1 0 4
Prognosis
Recurrent 11 18 81
Dropped 3 2 10
Following 18 9 6
Median PFS
(mo)
104 31 6
Median OS (mo) Undeﬁned 67 17
A comparison of patient backgrounds according to histological classiﬁcation (A) and genetic classiﬁcation (B). In this table, oligoastrocytomas were
classiﬁed as oligodendroglial tumor.
doi:10.1371/journal.pone.0142750.t001
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mutant gliomas with TP53mutations had at least one of the CNAs +7q, +8q, −9p, and −11p
(Fig 3), and those CNAs overlapped with −1p/19q in tumors lacked TP53mutations. IDH
mutant gliomas with and without +7q, +8q, −9p, and −11p are summarized in Table 2.
Because TP53mutations in IDHmutant gliomas were indicative of a poor prognosis and as
+7q, +8q, −9p, and −11p were frequently observed in IDHmutant gliomas with TP53muta-
tions, we hypothesized that these CNAs were associated with a poor prognosis in patients with
IDHmutant gliomas. Accordingly, patients with IDHmutant gliomas who harbored at least
one of the abovementioned CNAs had a significantly worse prognosis than did patients with
IDHmutant gliomas without these CNAs (p< 0.0001; Fig 1E and 1F). The median PFS was 31
months for patients with IDHmutant gliomas harboring +7q, +8q, −9p, and/or −11p com-
pared with 78 months for all other IDHmutant gliomas (hazard ratio = 0.254; 95% CI: 0.128–
0.506; p< 0.0001). The median OS for patients with IDHmutant gliomas who harbored these
CNAs was 65 months, whereas the median OS for all others could not be defined (hazard
ratio = 0.255; 95% CI: 0.111–0.586; p< 0.0001). In addition, a multivariate logistic regression
analysis revealed that the 3-year recurrence rate was higher for patients with gliomas who
Fig 2. CNAs frequently detected in IDHmutant gliomas. A comparison of CNAs found in IDHmutant gliomas (A) with wild-type TP53 and (B) mutant
TP53. The number of CNAs detected in both IDHmutant gliomas with wild-type and mutant TP53 is summarized in a table.
doi:10.1371/journal.pone.0142750.g002
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harbored these CNAs than for patients with other types of gliomas (S1 Table). Therefore, +7q,
+8q, −9p, and −11p should be considered negative prognostic factors in IDHmutant gliomas.
The CNAs +8q, −9p, −11p, and +12p are candidate markers for tumor
progression in IDHmutant gliomas
In the present copy number analyses, gliomas with +7q were mainly detected in cases involving
first surgeries. However, tumors harboring +8q, −9p, −11p, and +12p were frequently found
after subsequent surgeries (Fig 3); +7q, +8q, −9p, −11p, and +12p emerged between the initial
surgery and recurrent surgical interventions in 0, 2, 4, 3, and 4 cases of IDHmutant gliomas
with TP53mutations, respectively. Moreover, +7q was frequently detected in grade II gliomas,
whereas +8q, −9p, −11p, and +12p were observed in high grade cases. These observations sug-
gest that +7q is an early event, whereas +8q, −9p, −11p, and +12p may reflect tumor progres-
sion in IDHmutant gliomas with TP53mutations. Among patients with IDHmutant gliomas
with TP53mutations, the median PFS was 31 months for gliomas harboring any one of +8q,
−9p, −11p, or +12p compared with 47 months for patients harboring all other CNAs (n = 24;
p = 0.067). On the other hands, the average MIB-1 indexes was 25.4% among cases harboring
+8q, −9p, −11p, and/or +12p and 8.04% in gliomas without these CNAs (n = 31; p = 0.011).
These results suggest that malignancy-related genes are present in these regions.
Fig 3. The correlation between TP53mutations and the CNAs −1p/19q, +7q, +8q, −9p, and −11p in IDHmutant gliomas. A comparison between (A)
primary (n = 47) and (B) recurrent disease (n = 24). The CNA −1p/19q represents a favorable prognostic marker; the CNAs +7q, +8q, −9p, and −11p
represents unfavorable prognostic markers.
doi:10.1371/journal.pone.0142750.g003
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Table 2. A list of IDHmutant glioma patients with (A) and without (B) +7q, +8q, −9p, and/or −11p according to comparative genomic hybridization
(CGH) analysis as well as their prognosis and TP53mutation status.
A
Histology Age,
Sex
Surgery CNAs Genetic
type
TP53 mut Tumor
regrowth
PFS,
mo
Follow-
up, mo
Outcome
A GII 22M 1st +8q21.3-ter, +10pter-q23, −10q25-ter, −X +8q NA No 85 85 Alive
A GII*1 25M 1st −4q22-ter, +5pter-23.3, −5q31.2-ter, +7,
+8q, +13, −19q, −22
+8q NA Yes 15 25 Dead
A GII 27M 1st +7q31.3-ter, +10, +20 +7q p.K132fs No 30 30 Alive
A GII 28F 1st −6q, +8q21.1-ter, −9p, −14q22-ter, −Xp +8q, −9p NA Yes 62 77 Dead
A GII 30F 1st −6q, −9p, −14q22-ter, −19q −9p p.D281G Yes 41 67 Alive
A GII*2 33M 1st +8q22.3-ter, −12q13-24.1 +8q p.R273H Yes 12 83 Alive
A GII 35F 1st −4q, +6petr-q21, −8p21, +8q21.1–22,
−13q22-ter, −14q21-ter
+8q NA Yes 76 76 Alive
A GII*3 44F 1st −3p22-21, +7q, +8q22-ter, +11q23.3-ter,
+12p, −13q21-31, −19q
+7q, +8q p.R273C Yes 27 65 Dead
A GII 45M 1st +8q21.1–24.1, −11q23-ter, +19 +8q NA No 48 48 Alive
A GII 46F 1st +7q, −19q +7q p.H179Y No 14 14 Alive
A GII 54F 1st −4q, +8, +10pter-q22.3, −11p −11p p.N247S No 15 15 Alive
A GII 56F 1st +7q, −10, +19q, +20 +7q NA Yes 5 9 Dead
A GII 57F 1st +1q31-ter, −11p, +12p, −12q12-22,
+12q23-ter, −18, −19q, −20p, −21
−11p NA No 2 2 Alive
A GIII 27F 1st −3p21-13, +7p, +8q, +10p, −13q,
+14q24.3-ter, −16q, −19q, −X
+8q NA Yes 13 32 Dead
A GIII 35F 1st −11, −17p, −18q, −20p −11p p.R175H Yes 31 37 Dead
A GIII 35M 1st −11, −12q −11p p.R273C No 9 9 Alive
A GIII 39F 1st +1q21-31, −1q32.2-ter, +2p16-11.2, −5q,
−6q, +7q, +8q23-ter, −9q22-33, −10p, +17q,
−19q, −Xp
+7q, +8q NA No 18 18 Alive
A GIII 40F 1st +10q23-ter, −11, −13, −14, −17p, +17q, −18 −11p NA Yes 4 4 Alive
A GIII 43M 1st +8q, +12p, -19q, +20, +X +8q NA Yes 50 50 Alive
A GIII 47F 1st −8p, −9p, +9q, −10q24-ter, +12q14-15,
−12q21-ter, −14q21-31
−9p p.R273C Yes 21 36 Dead
A GIII*4 48M 1st −4q13-21, +7q, +13q31-ter, +X +7q p.R175H Yes 51 67 Dead
A GIII*4 52M 2nd +2pter-22, +3pter-23, +4q21-24, +4q26-33,
−6pter-22, −6q21-ter, +7q,−9pter-21,
−12p13, +20q
+7q, −9p p.R175H Yes 1 67 Dead
A GIII 55M 1st −2pter-23, +2p21-13, +3pter-22,
+3q24.1-ter, −4q28, +8p, −8q12-13,
+8q21.3–22.3, −9p, −10q22.1-ter,
+12q13.1–23, −13q12.1–22, −17p, +17q,
+19q, −20p
+8q, −9p NA Yes 3 26 Dead
A GIII 59F 1st −4q, −5p, +7, +8q +8q NA No 10 10 Alive
A GIII 65F 1st +1p35-33, +1q, +3p22-21, -6, +7p,
+7q32-ter, +8q23-ter, +9pter-21, -9q, −10q,
−13, −14, +15q, -22q
+7q, +8q p.R244S,
p.R245D
Yes 10 30 Dead
A GIII*5 74F 2nd +1p21, +1q, +7p15-cen, +8q21.3, +10p,
+16p11.2, +16q
+8q p.A138V No 13 19 Dead
OA GII*6 34M 1st −1p, +2p, −9p, −19q −1p/19q,
−9p
none Yes 25 34 Alive
OA GII*7 39M 1st +7q, +10q24-ter +7q p.R175H Yes 47 60 Alive
OA GII*7 43M 2nd −5p, +7q, −18q +7q p.R175H No 11 60 Alive
OA GII 46F 1st +3p, −5p, +8, −11p, −13q12.1–21.3,
+13q22-ter
−11p p.R306X No 19 19 Alive
(Continued)
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Table 2. (Continued)
OA GI *8 61F 1st +7q31-ter, −X +7q p.Y163C Yes 20 74 Alive
OA GII*8 63F 2nd +7q31.1-ter, +12q22-ter, −Xp +7q p.Y163C No 7 74 Alive
OA GIII*9 30M 2nd −1p, −4, +7q21.3-ter, +8, +11, −14q22-23,
−18, −19q
−1p/19q,
+7q
none Yes 16 111 Alive
OA GIII*2 34M 2nd +4p, −4q, −5qcen-13, −5q21-ter, +8q13-ter,
−9pter-21.3, −11p, +12p, −12q22-23
+8q, −9p,
−11p
p.R273H Yes 48 83 Alive
OA GIII 36F 1st −1q41-ter, −6q, +7q31-ter, −9p, −14q22-ter,
−Xq21-ter
+7q, −9p p.G245S No 36 36 Alive
OA GIII 40F 1st −1p, +1q, +3, −9, +12q14, −15q, +17, +18,
−19q, +20
−1p/19q,
−9p
none Yes 105 115 Alive
OA GIII*10 44F 3rd +2p, −3p21.3–11.2, +7, +8q23-ter, +10pter-
12.3, −19q13.2-ter
+8q p.Y220C Yes 2 80 Alive
OA GIII*3 47F 2nd −4q28-ter, +7q, +8q23-ter, +12p, −Xq +7q, +8q p.R273C Yes 29 65 Dead
OA GIII*5 74F 1st +1p21, +1q, +2p16-ter, +2q, −3p21, +7p21,
+7qcen-21, +8, +10p, +10qcen-24, +11,
+12p, -12q14-23, +16q
+7q p.A138V Yes 6 19 Dead
O GII 57F 1st −1p, −9pter-21, −18, −19q, +21 −1p/19q,
−9p
none No 51 51 Alive
O GII 59M 1st +7q, +8q21.1-ter, +10p, −13q14-32, −16q,
−19q
+7q, +8q p.R248W No 36 36 Alive
O GII 71M 1st −6pter-16, +8q21.1–21.3 +8q NA No 40 40 Alive
O GIII*11 37F 2nd −1p, +1q, −2, +6, +7, +8, −9, +11, −16, +17,
−18, +19p, −19q, +21, −22
−1p/19q,
−9p
none No 8 26 Alive
O GIII 41M 5th −1p, +7q, +8, +18p, −18q, −19q, +22q −1p/19q,
+7q
none Yes 5 76 Dead
O GIII 62M 1st −1p, +7q31.1-ter, −19q −1p/19q,
+7q
none No 0 0 Dead
O GIII*12 64M 2nd −1p, +2, +7, −9p, +9q, −15q, −19q −1p/19q,
−9p
none Yes 27 134 Alive
O GIII 72M 1st +1q, −2q37, −4p, +4q, −6pter-21.3,
−6q16-ter, −8, −9pter-23, −11p, −14q, −17p,
+17q22-ter
−9p, −11p p.R248W Yes 4 15 Dead
GBM*1 26M 2nd −3q11.2–24, +3q24.1-ter, +4p, −4q, +5pter-
5q23.3, −5q31.2-ter, −6pter-22.1, +6p22.2–
18.3, −6q21-26, +7, +8q, −9p, +13, −14q,
+16q, +17q, −18, −19q, +21, −22
+8q, −9p none Yes 1 25 Dead
GBM*13 28F 2nd −3pter-3q24, −5p, +7, −11p, −11q22-23.1,
−13q, −19q, −22, −X
−11p p.Y220C,
p.R248W
No 24 102 Alive
GBM*14 28M 3rd −4q28-ter, +5pter-q23.3, +7q, +8q, −9p,
−9q, −11pter-15.1, −11q23.1-ter, +12p,
−13q21.1–22, +13q31-ter
+7q, +8q,
−9p
p.Y236D Yes 4 67 Dead
GBM 62M 1st +2, −6p, −7p, +7q, +8q22-ter, −9p, +9q,
−11, −13q, −14q, +15q, +18q21
+7q, +8q,
−9p, −11p
NA Yes 3 4 Dead
ND*14 26M 1st +7q, +8q22.1-ter, +11q23.3-ter, +12p, +19 +7q, +8q NA Yes 27 67 Dead
ND*14 30M 4th +7q, +8q, −9p, −X +7q, +8q,
−9p
p.Y236D Yes 4 67 Dead
ND*2 38M 3rd −5q31.1-ter, +8q22.3-ter, +10p, −10q, +12p +8q p.R273H No 20 83 Alive
B
A GII*13 22F 1st −11q22-23.1 another p.Y220C,
p.R248W
Yes 78 102 Alive
A GII*15 22F 1st none none p.H193Y Yes 72 85 Alive
A GII 37M 1st +2q24-33, −3p22-q25, −4q28-ter, +7 another NA No 7 7 Alive
A GII 38F 1st −1p, −19q −1p/19q none No 14 14 Alive
(Continued)
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Table 2. (Continued)
A GII 41M 1st −4 another p.H179R No 9 9 Alive
A GIII 55M 1st −1p, +7, −10p, −19q −1p/19q NA No 12 12 Alive
A GIII 60M 1st −1p, −4, −9q22-ter, −14q21.3-ter, −19q −1p/19q NA No 118 118 Alive
OA GII*9 24M 1st −1p, −19q −1p/19q none Yes 69 111 Alive
OA GII 31F 1st −12q, −13q14.3–22 another none No 5 5 Alive
OA GII 34F 1st −1p, −19q −1p/19q none No 55 55 Alive
OA GII 34M 1st −1p, −14q, −19q −1p/19q none No 161 161 Alive
OA GII*16 35F 1st −1p, −19q −1p/19q none Yes 52 102 Alive
OA GII 37M 1st −1p, −14, −19q −1p/19q none Yes 35 35 Alive
OA GII*10 40F 2nd +7 another p.Y220C Yes 22 80 Alive
OA GII 41M 1st −4q26-ter, −5q21-ter, +7, −11q, −12q another none No 79 79 Alive
OA GII 41F 1st −1p, −19q −1p/19q none No 43 43 Alive
OA GII 44F 1st −1p, −14q, −19q −1p/19q none No 81 81 Alive
OA GII 45F 1st −1p, +7, −19q −1p/19q none No 5 5 Alive
OA GII 48M 1st −1p, −19q −1p/19q none No 39 39 Alive
OA GIII*15 28F 2nd −13q22, +18p, +19, −X another p.H193Y No 4 85 Alive
OA GIII*17 29M 1st −1p, −19q −1p/19q none Yes 49 68 Alive
OA GIII*9 32M 3rd −1p, +3, −4, +5, +7, +9q, +10p, −10q, −13q,
−15q11.2–22.3, +15q22.2-ter, −19q
−1p/19q none Yes 11 111 Alive
OA GIII*17 34M 2nd −1p, −19q −1p/19q none No 9 68 Alive
OA GIII 35M 1st −1p, −4, −13, −18, −19q −1p/19q none No 40 40 Alive
OA GIII 36M 1st −1p, −4, +11, −19q −1p/19q none No 116 116 Alive
OA GIII 37F 1st −1p, −14q13-24, −19q −1p/19q none No 151 151 Alive
OA GIII 43M 1st −1p, +1q12-32.1, −1q32.2-ter, +11, +17,
+19p, −19q
−1p/19q none Yes 44 64 Dead
OA GIII 44M 1st −1p, −19q −1p/19q none No 11 11 Alive
OA GIII 74M 1st +1q, +3, +4q12-24, −5q13.1–14, +9p, −14q,
−18p
another NA No 3 3 Alive
O GII 33M 1st −1p, −14q22-24.3, −19q −1p/19q NA No 15 15 Alive
O GII*18 34M 1st −1p, −14, −19q −1p/19q none Yes 63 69 Alive
O GII 52F 1st −1p, −4, +7, +11q, −15q21-ter, −18q, −19q −1p/19q NA No 12 12 Alive
O GII*12 53M 1st −1p, +7, −15q, −19q, +22q −1p/19q none Yes 104 134 Alive
O GIII*9 34M 4th −1p, −4, −10q, −13q, −14q, −15qcen-21,
+15q24-ter, −19q
−1p/19q none Yes 9 111 Alive
O GIII*11 36F 1st −1p, −19q −1p/19q none Yes 17 26 Alive
O GIII*6 36M 2nd −1p, −17p, −18q, −19q −1p/19q none No 7 34 Alive
O GIII*18 39M 2nd −1p, −14q, −19q, +21q −1p/19q none No 6 69 Alive
O GIII*16 40F 2nd −1p, +11, −14, −19q −1p/19q none No 48 102 Alive
O GIII*19 57M 2nd −1p, −14q13-24, −19q −1p/19q none Yes 12 85 Alive
O GIII*19 58M 3rd −1p, +7, −14q21-24.3, −15q15-22.1, −19q −1p/19q none Yes 6 85 Alive
O GIII 68F 1st −1p, +2, −3p, +3q, −4, +5, +7, +8, +9q, 13q,
+14q, +17, −19q
−1p/19q none No 21 21 Alive
The genetic type indicates detected the CNAs which are regarded as a favorable CNA (–1p/19q) or unfavorable CNAs (+7q, +8q, −9p, and/or −11p). A
repeated number denoted by an asterisk indicates ta single patient who underwent multiple surgeries. Abbreviations: NA, not available.
doi:10.1371/journal.pone.0142750.t002
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Discussion
From this study, we report two major findings. First, we have shown that copy number-inde-
pendent genetic subgroups determined using IDH1/2 and TP53 as markers for Sanger sequenc-
ing could sufficiently substitute for genetic classification with 1p/19 co-deletions. Second, via a
whole-chromosome CNA analysis of IDHmutant gliomas with TP53mutations, we have clari-
fied the CNAs that contribute to poor prognosis in patients with IDHmutant gliomas.
Previous studies have confirmed that specific genetic features including IDHmutation and
1p/19p co-deletions are excellent prognostic markers for gliomas [17, 18]. In the present study,
we aimed to identify copy number-independent methods that would allow a widespread clini-
cal application of genetic classification of gliomas. Several previous studies reported various
prognostic genes identified via mutation analyses, and ATRX and TERT promoters have
recently been recognized as prognostic markers of gliomas [6, 19, 20]. In the present study, we
selected TP53 as a prognostic marker because gliomas with 1p/19q co-deletions and TP53
mutations were previously shown to be mutually exclusive [8]; accordingly, we hypothesized
that IDHmutant gliomas with wild-type TP53 would predominantly harbor 1p/19q co-dele-
tions. Our results support the previous finding that 1p/19q co-deletions and TP53mutation
are mutually exclusive. The survival curves for patients with gliomas carrying 1p/19q co-dele-
tions were almost identical to those of patients with wild-type TP53, suggesting that wild-type
TP53 is sufficiently indicative of 1p/19q co-deletions. In addition to the convenience of PCR-
based TP53mutation analysis, we are now investigating the relevance of prognosis, CNA, and
the mutated TP53 exon for demonstrating the advantage of subgrouping according to TP53
mutation versus subgrouping according to 1p/19q co-deletions. IDH and TP53mutant gliomas
that carry +7q also tend to carry mutations in TP53 exon 5, suggesting that an exon 5 mutation
is associated with a better prognosis in IDH and TP53mutant gliomas comparing with other
types of IDH and TP53mutant gliomas. However, the sample size is extremely low, and we
would need to increase the number of analyzed samples to support this conclusion.
As shown in Fig 1E and 1F, IDHmutant gliomas harboring any one of the CNAs +7q, +8q,
−9p, or −11p were associated with a significantly worse survival when compared with other
IDHmutant gliomas, indicating that these CNAs are negative prognostic factors for IDH
mutant gliomas. Several studies previously reported that specific CNAs were candidate nega-
tive prognostic markers in gliomas. Our previous studies suggested that gliomas carrying +7q
were more likely to be associated with a shorter PFS than were gliomas carrying −1p/19q; −9p
was found to be a negative prognostic factor in grade II and III gliomas [1]. Moreover, Kitange
et al. and Trost et al. indicated that +8q was associated with short survival durations in patients
with oligodendrogliomas [21, 22], and recent studies have reported that −10q, −11p, and −19q
were negative prognostic factors for low grade gliomas [16, 23]. Via a whole-chromosome anal-
ysis of CNAs for IDHmutant gliomas with TP53mutations, we clarified that +7q, +8q, −9p,
and −11p are unfavorable prognostic factors for IDHmutant gliomas. In addition, because
+12p was unique to IDHmutant gliomas with TP53mutations, we suspected that this CNA
will be associated with poor survival in patients with IDHmutant gliomas. Accordingly, this
CNA tended to emerge in cases involving recurrent surgical interventions or high grade glio-
mas (Figs 2 and 3). However, correlations between gliomas and +12p remain elusive. The chro-
mosomal regions 7q, 8q, 9p, 11p, and 12p contain various oncogenes or tumor suppressor
genes, includingMET (7q31),MYC (8q24.21), CDKN2A (9p21), CDKN1C (11p15.5), and
KRAS (12p12.1), and these genes might be associated with tumor progression in IDHmutant
gliomas with TP53mutations. The mechanisms underlying the associations of TP53mutations
with CNAs in the abovementioned specific regions remain unclear. p53 is a transcription factor
that regulates target genes in response to DNA damage and is best known as a tumor
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suppressor gene [24]. Recent studies have correlated the absence of TP53 with chromosome
segregation errors and chromosomal instability [25, 26], suggesting that TP53mutations occur
during the early phase of tumorigenesis in IDHmutant gliomas and cause chromosomal insta-
bility and gene dysregulation in specific regions such as 7q, 8q, 9p, 11p, or 12p. Further studies
of these chromosomal changes may facilitate interpretations of tumor growth processes in IDH
mutant gliomas with TP53mutations.
Our results confirmed that most IDHmutant gliomas with TP53mutations involve at least
one of the CNAs +7q, +8q, −9p, and −11p, and that most IDHmutant gliomas with wild-type
TP53 carry 1p/19q co-deletions. On the other hands, +7 and −10q are frequently detected in
IDH wild-type gliomas [5]. These results suggest that gliomas can be separated into different
lineage depending on IDHmutation, and IDHmutant gliomas are further separated into two
distinct linages according to the TP53mutation developing the specific CNAs in each lineage.
As mentioned above, TP53mutation did not affect the prognosis of patients with IDH wild-
type gliomas. In a comparison of prognosis between IDH wild-type gliomas and primary glio-
blastomas, the median PFS (6 and 6 months, respectively) and median OS (17 and 15 months,
respectively) were almost identical, suggesting that histological diagnosis can sufficiently pre-
dict prognosis in cases of primary glioblastomas.
Given the high recurrence rate among IDHmutant gliomas with TP53mutations, efforts
are required to prevent progression to high grade gliomas or secondary glioblastomas, which
are difficult to control with multidisciplinary treatments. To this end, studies are in progress
now using OncoScan arrays (Affymetrix) for this type of glioma to identify specific regions
with common losses, gains, or high copy number gains, and consequent changes in gene
expression. In addition, some patients with 1p/19q co-deleted gliomas developed recurrence
within a few years and these gliomas lacked TP53mutations, suggesting the presence of other
genes that contribute to a poor prognoses in patients with IDHmutant gliomas.
In this study, we showed that PCR-based mutation analyses using IDH1/2 and TP53 as
markers could rapidly and simply classify glioma with prognostic relevance. Although patho-
logical diagnoses facilitate evaluations of malignancy at the time of surgery, genetic classifica-
tions provide better prognostic predictions, particularly in cases of WHO grade II and III
gliomas. Specifically, IDHmutant gliomas carrying at least one of the CNAs +7q, +8q, −9p, or
−11p were associated with a shorter survival and were predominantly associated with TP53
mutations. In conclusion, both pathological and genetic classifications are essential for glioma
diagnosis and the present observations could be used to facilitate genetic classification.
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